Trial of OMN6 for hospital-acquired Acinetobacter pneumonia
Part of Lungs & breathing clinical trials.
This trial tests a new antibiotic called OMN6 for people with a serious lung infection (pneumonia) caught in the hospital or from a breathing machine, caused by a hard-to-treat bacteria (Acinetobacter). The goal is to see if OMN6 is safe and how the body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have signed a consent form.
- You must have hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP).
- A lab test has to show your lung infection is caused by Acinetobacter bacteria.
- Your severity score (APACHE II) must be between 10 and 24.
- If you are a woman who can get pregnant, you need a negative pregnancy test before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
This trial tests a combination of two antibiotics (meropenem and pralurbactam) to see if they work better than other treatments for people with pneumonia that started in the hospital or from a breathing machine. If you qualify, this study might offer you a new treatment option.
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
This trial tests a drug called Polymyxin E2 Methanesulfonate for a serious lung infection that patients can get in the hospital, caused by bacteria that don't respond to common antibiotics. It may be an option for people on ventilators or recently hospitalized with pneumonia that standard drugs can't treat.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
Hear when a new Hospital-acquired Bacterial Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.